SHR-A1811 and pertuzumab before surgery for HER2-positive breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized Phase 2 trial enrolls adults with early or locally advanced HER2-positive invasive breast cancer and assigns them 1:1:1 to one of three 6-cycle neoadjuvant regimens: SHR-A1811 plus pertuzumab, SHR-A1811 plus pertuzumab and albumin-paclitaxel, or a standard TCbHP regimen (docetaxel, carboplatin, trastuzumab, pertuzumab). The primary endpoint is pathologic complete response (pCR) after neoadjuvant therapy, with safety and tolerability monitored as key secondary outcomes. Eligible participants must have measurable primary lesions, adequate organ and bone marrow function, and preserved cardiac function. The trial is conducted at Henan Cancer Hospital and directly compares the new SHR-A1811-containing combinations against the current standard regimen.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age: 18-70 years old, ECOG 0-1 point.
* Clinical T2-T4, with any LN, M0.
* HER2+, invasive breast cancer confirmed by histopathology;(HER2 positive expression means that there is at least one case of tumor cell immunohistochemical staining intensity of 3+or positive confirmed by fluorescence in situ hybridization \[FISH\] in the pathological test/review of the primary focus conducted by the Pathology Department of the Research Center Hospital).
* Having clinically measurable lesions: measurable lesions displayed on ultrasound, mammography, or MR (optional) within the first month of randomization.
* Organ and bone marrow function tests within one month before chemotherapy indicate no contraindications to chemotherapy：Absolute value of neutrophil count ≥ 1.5 × 10\^9/L; Hemoglobin ≥ 90g/L; Platelet count ≥ 100 × 10\^9/L; Total bilirubin≤1.5 ULN (upper limit of normal value); Creatinine≤1.5 × ULN; AST/ALT ≤ 2.5 × ULN.
* Cardiac ultrasound: Left ventricular ejection fraction (LVEF ≥ 50%).
* Women of childbearing age tested negative for serum pregnancy test 7 days before randomization.
* Sign an informed consent form.

Exclusion Criteria:

* Stage IV (metastatic) breast cancer.
* Has received chemotherapy, endocrine therapy, targeted therapy, reflex therapy, etc. for this disease.
* The patient has a second primary malignant tumor, except for fully treated skin cancer.
* The patient had undergone major surgical procedures unrelated to breast cancer within 4 weeks before enrollment, or the patient has not fully recovered from such surgical procedures.
* The presence of uncontrolled cardiovascular and cerebrovascular disease, including (but not limited to) any of the following within the 6 months prior to the first dose: congestive heart failure (NYHA III or IV), myocardial infarction or cerebral infarction, pulmonary embolism, unstable angina, or arrhythmia requiring treatment at the time of screening; Primary cardiomyopathy (e.g., dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restricted cardiomyopathy, undefined cardiomyopathy); A clinically significant history of prolonged QTc, grade II type II atrioventricular block or grade III atrioventricular block or QTc interphase (F method) \> 470 msec (female); Atrial fibrillation (EHRA grade ≥2b); Unmanageable hypertension, which the investigators judged unsuitable for study participation.
* Due to serious and uncontrollable other medical diseases, researchers believe that there are contraindications to chemotherapy.
* Individuals with a known history of allergies to the drug components of this protocol;
* Having a history of immunodeficiency, including HIV testing positive, or suffering from other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation.

Where it's running

• Henan Cancer Hospital
  Zhengzhou, Henan, China Recruiting

Study contacts

• Principal investigator: Zhenzhen Liu — Henan Cancer Hospital
• Study coordinator: Zhenzhen Liu
• Email: liuzhenzhen73@126.com
• Phone: 86+13603862755

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant Pyrotinib-to-pertuzumab for HER2-positive early breast cancer

  This trial tests whether a two-step neoadjuvant plan with Pyrotinib plus Trastuzumab and Docetaxel followed by Pertuzumab plus Trastuzumab and Docetaxel works better than four cycles of Pertuzumab plus Trastuzumab and Docetaxel in women with HER2-positive early- to locally advanced breast cancer.

  Recruiting Phase 3 Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07797218

• Regular exercise to help women with early-stage breast cancer on hormone therapy

  This study tests whether a guided, 16-week exercise program improves quality of life and fitness for women with early-stage breast cancer who are starting adjuvant hormone therapy.

  Recruiting Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares · San Sebastián de los Reyes, Madrid · NCT07893327

• Olaparib with Trastuzumab and Pertuzumab before surgery for older women with HER2-positive breast cancer

  This trial tests whether adding olaparib to standard HER2-targeted therapy can help older women with newly diagnosed, operable HER2-positive breast cancer before surgery.

  Recruiting Phase 4 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07695259

• Paclitaxel micelles with HER2-targeted therapy vs standard taxane-based therapy as first-line treatment for advanced HER2-positive breast cancer

  This study tests whether paclitaxel polymer micelles plus trastuzumab, pertuzumab, and ad Adelumab can better treat advanced HER2-positive breast cancer compared with the usual taxane-based therapy plus trastuzumab and pertuzumab.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07581795

• Using a pertuzumab biosimilar for HER2-positive breast cancer before surgery and as first-line treatment for metastatic disease

  This project will look at how a pertuzumab biosimilar is used and how patients with HER2-positive breast cancer do when given it before surgery or as first-line treatment for metastatic disease.

  Recruiting at 2 sites Société Algérienne de Formation et Recherche en Oncologie · Algiers and 1 other locations · NCT07542496

• BL-M07D1 plus pertuzumab vs standard therapy in first-line HER2-positive breast cancer

  A Phase 3 trial tests whether adding BL-M07D1 to pertuzumab is as good as or better than docetaxel plus trastuzumab and pertuzumab in patients with newly diagnosed, unresectable or metastatic HER2-positive breast cancer.

  Recruiting at 2 sites Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong and 1 other locations · NCT07518173

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.